Bioenvision shareholders support Genzyme takeover

Bioenvision shareholders controlling a majority of the company's shares Monday voted in favor of Genzyme Corp.'s acquisition of the biotech firm for $345 million. The deal will give Genzyme exclusive, worldwide rights to clofarabine, a cancer drug it jointly developed with Bioenvision, further expanding its oncology offerings.

View Full Article in:

Boston Globe (tiered subscription model), The · International Herald Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY